Biodesix, Inc.
NASDAQ:BDSXMedical - Diagnostics & Research
+$2.04 today
- Market cap
- $68.38M
- Beta
- 0.59
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$3.31
Volume 0.17M
Average 0.06M
BDSX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Biodesix, Inc.NASDAQ: BDSX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $16.9M rose 17319.6% year over year, ahead of the -35.3% change in trailing-twelve-month financing cash flow. Sequentially, it rose 888.7% from the prior quarter. Over 3 fiscal years it compounded at -34.7% a year.
Context
- Financing cash flow amounted to 18.6% of revenue in FY2025, down 54.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17319.6% holds above the trailing-twelve-month pace of -35.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 16.42M USD
- Year-over-year change
- -68.5%
- 4-year CAGR
- +89.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.42M | -68.5% |
| FY2024 | 2024-12-31 | 52.05M | +78.7% |
| FY2023 | 2023-12-31 | 29.13M | -50.5% |
| FY2022 | 2022-12-31 | 58.88M | +4565.8% |
| FY2021 | 2021-12-31 | 1.26M | — |
Financing Cash Flow vs competitors
How BDSX compares with its peers on the latest reported figures
- BDSX's LTM Mar 2026 financing cash flow of $33.22M is the 4th largest of the 5 companies compared; the peer median is $70.49M.
- Its year-over-year change of -35.3% is the 4th highest of 5, against a peer median of +3.9%.
- Financing cash flow amounts to 34.6% of revenue for BDSX, versus a peer median of 221.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $674.37M | -9094.6% | +619.6% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $146.24M | +21.9% | -81.7% | — |
| LTM Mar 2026 | $118.65M | +258.7% | — | 221.8% | |
| LTM Mar 2026 | $33.22M | -35.3% | -34.7% | 34.6% | |
| LTM Mar 2026 | $22.34M | -14.0% | +235.8% | — | |
| Peer median (excluding BDSX) | $70.49M | +3.9% | +235.8% | 221.8% | |
Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.16M) | (65.45M) | (52.15M) | (42.93M) | (35.27M) |
| Depreciation & Amortization | 3.18M | 5.84M | 5.51M | 5.46M | 5.6M |
| Deferred Income Tax | (2.11M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.94M | 5.96M | 5.37M | 6.64M | 4.14M |
| Change in Working Capital | 4.59M | (4.34M) | 11.3M | (21.67M) | 334K |
| Accounts Receivables | 11.45M | (1.5M) | (4.72M) | (1.81M) | (531K) |
| Inventory | 7.43M | 906K | 166K | 22K | 0 |
| Accounts Payables | (7.43M) | (773K) | 513K | 1.64M | 0 |
| Other Working Capital | (6.86M) | (2.98M) | 15.34M | (21.52M) | 865K |
| Other Non-Cash Items | 4.33M | 13.01M | 7.09M | 3.86M | 1.92M |
| Operating Cash Flow | (28.22M) | (44.97M) | (22.87M) | (48.65M) | (23.27M) |
| Capital Expenditures | (2.55M) | (3.53M) | (23.06M) | (3.23M) | (403K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (306K) | (236K) | (143K) | (210K) | (144K) |
| Investing Cash Flow | (2.55M) | (3.53M) | (23.06M) | (3.44M) | (403K) |
| Debt Repayment | (15.35M) | 16.5M | 9.95M | (51K) | 9.98M |
| Common Stock Issued | 16.34M | 59.54M | 28.13M | 55.63M | 7.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 269K | (17.15M) | (8.95M) | (3.52M) | (1.38M) |
| Financing Cash Flow | 1.26M | 58.88M | 29.13M | 52.05M | 16.42M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.51M) | 10.38M | (16.8M) | (39K) | (7.26M) |
| Free Cash Flow | (30.77M) | (48.51M) | (45.93M) | (51.88M) | (23.67M) |
Biodesix, Inc.
NASDAQ:BDSX
Intrinsic Alpha fair value
Locked
Current Price
$8.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.